Trial Profile
A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OUTRUN
- 08 Nov 2020 Planned End Date changed from 1 Mar 2022 to 1 Mar 2024.
- 08 Nov 2020 Planned primary completion date changed from 1 Sep 2021 to 1 Aug 2023.
- 21 Nov 2019 Status changed from not yet recruiting to recruiting.